

ASX ANNOUNCEMENT 9 September 2005

HeartWare is pleased to announce that Professor Gerry O'Driscoll has joined the Company's Medical Advisory Board.

Professor Gerry O'Driscoll to Join HeartWare's Medical Advisory Board

Professor O'Driscoll is a Consultant Cardiologist at the Royal Perth Hospital, where he is Medical Head of West Australian Advanced Heart Failure & Cardiac Transplant Services. He is Research Head of the Cardiovascular Research Group at Royal Perth Hospital and a Board Member of the Heart & Lung Transplant Foundation of Western Australia. He serves as a funding reviewer for the National Heart Foundation and National Health and Medical Research Council and is a member of several national committees in clinical cardiology. He is also a reviewer for a number of international scientific journals. Professor O'Driscoll has extensive experience in the area of mechanical circulatory assist, having been involved for over a decade in the use of a wide range of ventricular assist devices.

HeartWare CEO, Mr Stuart McConchie, commented on the appointment:

"HeartWare's Medical Advisory Board includes several of the world's best regarded cardiologists and cardiac surgeons. We look regularly to these clinicians for guidance and have found their collective expertise invaluable in the lead up to HeartWare's first human implant. With Australia expected to play an important role in our forthcoming clinical trial, we are delighted to welcome one of this country's most experienced heart failure cardiologists to our Advisory Board. We look forward to working with Professor O'Driscoll."

Following Professor O'Driscoll's appointment, HeartWare's Medical Advisory Board includes the following seven clinicians:

Bud Frazier, MD	Chief of Transplant Service	es and Director Cardiovascular	Research,
-----------------	-----------------------------	--------------------------------	-----------

(Chairman) Texas Heart Institute, USA

Steven Boyce, MD Director of Heart Transplantation and Cardiac Assist Device

Programmes, Washington Hospital Centre, USA

Laman A. Gray, Jr., MD Professor of Surgery and Director of Thoracic and Cardiovascular

Surgery, University of Louisville School of Medicine, USA

Leslie Miller, MD Professor of Medicine and Director of Heart Failure Program, University

of Minnesota, USA



Gerry O'Driscoll, MD Head of Heart Failure and Cardiac Transplantation, Royal Perth

Hospital, Australia

Stephen Westaby, MD Cardiothoracic Surgeon, John Radcliffe Hospital, UK

Georg Wieselthaler, MD Clinical Director of Mechanical Circulatory Support, Vienna General

Hospital, Austria

About HeartWare

HeartWare is developing a family of proprietary circulatory assist devices to treat patients with congestive heart failure. Heart failure affects 10 million people globally, with over one million new patients diagnosed every year. Some 100,000 patients per year are expected to be eligible for device based treatment.

HeartWare's first left ventricular assist device, the HVAD, is expected to commence human clinical trials in early 2006, with first sales planned for 2007. With a volume of 45cc, the HVAD is substantially smaller than other "third generation" full output pumps in development, giving rise to significant potential clinical advantages.

For further information:

www.heartware.com.au

Howard Leibman Director Corporate Development HeartWare Limited (02) 8215 7604 / 0402 440644 Stuart Barton / Paula Hannaford Gavin Anderson & Company 0413 940 180 / 0404 054 857